ID   TACY_STRP2              Reviewed;         471 AA.
AC   Q04IN8; P11990;
DT   06-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   14-NOV-2006, sequence version 1.
DT   28-JAN-2026, entry version 107.
DE   RecName: Full=Pneumolysin;
DE            Short=PLY;
DE   AltName: Full=Thiol-activated cytolysin;
GN   Name=ply; OrderedLocusNames=SPD_1726;
OS   Streptococcus pneumoniae serotype 2 (strain D39 / NCTC 7466).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Lactobacillales; Streptococcaceae;
OC   Streptococcus.
OX   NCBI_TaxID=373153;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 2-17.
RC   STRAIN=D39 / NCTC 7466;
RX   PubMed=3552992; DOI=10.1128/iai.55.5.1184-1189.1987;
RA   Walker J.A., Allen R.L., Falmagne P., Johnson M.K., Boulnois G.J.;
RT   "Molecular cloning, characterization, and complete nucleotide sequence of
RT   the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus
RT   pneumoniae.";
RL   Infect. Immun. 55:1184-1189(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=D39 / NCTC 7466;
RX   PubMed=17041037; DOI=10.1128/jb.01148-06;
RA   Lanie J.A., Ng W.-L., Kazmierczak K.M., Andrzejewski T.M., Davidsen T.M.,
RA   Wayne K.J., Tettelin H., Glass J.I., Winkler M.E.;
RT   "Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus
RT   pneumoniae and comparison with that of unencapsulated laboratory strain
RT   R6.";
RL   J. Bacteriol. 189:38-51(2007).
RN   [3]
RP   FUNCTION, DOMAIN, AND MUTAGENESIS OF CYS-428; TRP-433; GLU-434; TRP-435 AND
RP   TRP-436.
RC   STRAIN=D39 / NCTC 7466;
RX   PubMed=9445384; DOI=10.1042/bj3290571;
RA   Korchev Y.E., Bashford C.L., Pederzolli C., Pasternak C.A., Morgan P.J.,
RA   Andrew P.W., Mitchell T.J.;
RT   "A conserved tryptophan in pneumolysin is a determinant of the
RT   characteristics of channels formed by pneumolysin in cells and planar lipid
RT   bilayers.";
RL   Biochem. J. 329:571-577(1998).
RN   [4]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=15851031; DOI=10.1016/j.cell.2005.02.033;
RA   Tilley S.J., Orlova E.V., Gilbert R.J., Andrew P.W., Saibil H.R.;
RT   "Structural basis of pore formation by the bacterial toxin pneumolysin.";
RL   Cell 121:247-256(2005).
RN   [5]
RP   FUNCTION, CHOLESTEROL-BINDING, AND MUTAGENESIS OF 459-THR-LEU-460.
RX   PubMed=20145114; DOI=10.1073/pnas.0911581107;
RA   Farrand A.J., LaChapelle S., Hotze E.M., Johnson A.E., Tweten R.K.;
RT   "Only two amino acids are essential for cytolytic toxin recognition of
RT   cholesterol at the membrane surface.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4341-4346(2010).
RN   [6] {ECO:0007744|PDB:5CR6, ECO:0007744|PDB:5CR8}
RP   X-RAY CRYSTALLOGRAPHY (1.98 ANGSTROMS), FUNCTION, ACTIVITY REGULATION,
RP   DOMAIN, AND MUTAGENESIS OF THR-88; ARG-147; ASP-205; ARG-226; THR-304;
RP   ASN-339 AND 434-GLU--ARG-437.
RC   STRAIN=D39 / NCTC 7466;
RX   PubMed=26333773; DOI=10.1038/srep13293;
RA   Marshall J.E., Faraj B.H., Gingras A.R., Lonnen R., Sheikh M.A.,
RA   El-Mezgueldi M., Moody P.C., Andrew P.W., Wallis R.;
RT   "The Crystal Structure of Pneumolysin at 2.0 A Resolution Reveals the
RT   Molecular Packing of the Pre-pore Complex.";
RL   Sci. Rep. 5:13293-13293(2015).
RN   [7] {ECO:0007744|PDB:4ZGH}
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 2-470, DOMAIN, AND MUTAGENESIS OF
RP   LYS-18; 66-ASN--SER-68; ASN-66; SER-68 AND LYS-208.
RC   STRAIN=D39 / NCTC 7466;
RX   PubMed=26403197; DOI=10.1038/srep14352;
RA   Lawrence S.L., Feil S.C., Morton C.J., Farrand A.J., Mulhern T.D.,
RA   Gorman M.A., Wade K.R., Tweten R.K., Parker M.W.;
RT   "Crystal structure of Streptococcus pneumoniae pneumolysin provides key
RT   insights into early steps of pore formation.";
RL   Sci. Rep. 5:14352-14352(2015).
RN   [8] {ECO:0007744|PDB:5AOD}
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS), DOMAIN, AND MUTAGENESIS OF THR-63;
RP   ASN-85; ASP-102; LYS-152; GLN-191; ASP-205; GLU-260; GLU-264 AND THR-405.
RX   PubMed=27796097; DOI=10.1021/acs.nanolett.6b04219;
RA   van Pee K., Mulvihill E., Mueller D.J., Yildiz O.;
RT   "Unraveling the Pore-Forming Steps of Pneumolysin from Streptococcus
RT   pneumoniae.";
RL   Nano Lett. 16:7915-7924(2016).
RN   [9] {ECO:0007744|PDB:5AOE, ECO:0007744|PDB:5AOF, ECO:0007744|PDB:5LY6}
RP   STRUCTURE BY ELECTRON MICROSCOPY (4.50 ANGSTROMS) OF WHOLE PORE, X-RAY
RP   CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF NON-HEMOLYTIC MUTANTS, PORE FORMATION,
RP   SUBUNIT, DOMAIN, AND MUTAGENESIS OF 146-ALA-ARG-147 AND ASP-168.
RC   STRAIN=D39 / NCTC 7466;
RX   PubMed=28323617; DOI=10.7554/elife.23644;
RA   van Pee K., Neuhaus A., D'Imprima E., Mills D.J., Kuhlbrandt W., Yildiz O.;
RT   "CryoEM structures of membrane pore and prepore complex reveal cytolytic
RT   mechanism of Pneumolysin.";
RL   Elife 6:0-0(2017).
CC   -!- FUNCTION: A cholesterol-dependent toxin that causes cytolysis by
CC       forming pores in cholesterol-containing host membranes. After binding
CC       to target membranes, the protein undergoes a major conformation change,
CC       leading to its insertion in the host membrane and formation of an
CC       oligomeric pore complex. Cholesterol is required for binding to host
CC       membranes, membrane insertion and pore formation; cholesterol binding
CC       is mediated by a Thr-Leu pair in the C-terminus. Can be reversibly
CC       inactivated by oxidation. {ECO:0000269|PubMed:15851031,
CC       ECO:0000269|PubMed:20145114, ECO:0000269|PubMed:26333773,
CC       ECO:0000269|PubMed:28323617, ECO:0000269|PubMed:9445384}.
CC   -!- ACTIVITY REGULATION: Erythrocytes hemolysis is inhibited by
CC       cholesterol. {ECO:0000269|PubMed:26333773}.
CC   -!- SUBUNIT: Elongated monomers align along their lengths, indicating
CC       intersubunit contacts and suggesting the prepore structure
CC       (PubMed:15851031, PubMed:26333773, PubMed:26403197, PubMed:27796097,
CC       PubMed:28323617). Modeling based on cryo-EM shows a homooligomeric pore
CC       complex containing 38-44 subunits; when inserted in the host membrane
CC       (Probable). The size of isolated pores is detergent-dependent; in
CC       amphipol A8-35 homogenous rings form with 42 subunits
CC       (PubMed:28323617). {ECO:0000269|PubMed:15851031,
CC       ECO:0000269|PubMed:26333773, ECO:0000269|PubMed:26403197,
CC       ECO:0000269|PubMed:27796097, ECO:0000269|PubMed:28323617,
CC       ECO:0000305|PubMed:15851031}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250|UniProtKB:P0C2J9}. Host
CC       cell membrane {ECO:0000269|PubMed:28323617,
CC       ECO:0000305|PubMed:15851031}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:28323617}. Note=Secreted as soluble protein by the
CC       accessory Sec system (By similarity). It then inserts into the host
CC       cell membrane and forms pores formed by transmembrane beta-strands
CC       (PubMed:15851031, PubMed:28323617). {ECO:0000250|UniProtKB:P0C2J9,
CC       ECO:0000269|PubMed:15851031, ECO:0000269|PubMed:28323617}.
CC   -!- DOMAIN: A highly conserved undecapeptide in the C-terminus has residues
CC       important for membrane binding and cell lysis (PubMed:9445384). Mature
CC       protein has 3 discontinuous domains; D1, D2, D3 followed by C-terminal
CC       D4 (PubMed:15851031, PubMed:26333773, PubMed:26403197, PubMed:27796097,
CC       PubMed:28323617). The domains rearrange substantially upon membrane
CC       insertion, in particular alpha-helices in D3 refold to form the
CC       transmembrane beta-strands (PubMed:15851031, PubMed:28323617). The
CC       relative position of domain D4 changes, allowing it to interact with
CC       host membranes (PubMed:26333773, PubMed:27796097, PubMed:28323617).
CC       {ECO:0000269|PubMed:15851031, ECO:0000269|PubMed:26333773,
CC       ECO:0000269|PubMed:26403197, ECO:0000269|PubMed:27796097,
CC       ECO:0000269|PubMed:28323617, ECO:0000269|PubMed:9445384}.
CC   -!- SIMILARITY: Belongs to the cholesterol-dependent cytolysin family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X52474; CAA36714.1; -; Genomic_DNA.
DR   EMBL; M17717; AAA26915.1; -; Genomic_DNA.
DR   EMBL; CP000410; ABJ53672.1; -; Genomic_DNA.
DR   RefSeq; WP_001284359.1; NC_008533.2.
DR   PDB; 4ZGH; X-ray; 2.90 A; A=2-470.
DR   PDB; 5AOD; X-ray; 2.40 A; A=1-471.
DR   PDB; 5AOE; X-ray; 2.50 A; A/B=1-471.
DR   PDB; 5AOF; X-ray; 2.45 A; A=1-470.
DR   PDB; 5CR6; X-ray; 1.98 A; D=1-471.
DR   PDB; 5CR8; X-ray; 2.05 A; A/D=359-471.
DR   PDB; 5LY6; EM; 4.50 A; B=1-471.
DR   PDB; 7T2A; X-ray; 3.04 A; C/F=429-441.
DR   PDB; 7T2B; X-ray; 2.80 A; C/H/M/R=429-441.
DR   PDB; 7T2C; X-ray; 3.10 A; C=429-441.
DR   PDB; 7T2D; X-ray; 3.40 A; C/H/M/R=429-441.
DR   PDBsum; 4ZGH; -.
DR   PDBsum; 5AOD; -.
DR   PDBsum; 5AOE; -.
DR   PDBsum; 5AOF; -.
DR   PDBsum; 5CR6; -.
DR   PDBsum; 5CR8; -.
DR   PDBsum; 5LY6; -.
DR   PDBsum; 7T2A; -.
DR   PDBsum; 7T2B; -.
DR   PDBsum; 7T2C; -.
DR   PDBsum; 7T2D; -.
DR   AlphaFoldDB; Q04IN8; -.
DR   EMDB; EMD-2611; -.
DR   EMDB; EMD-2612; -.
DR   EMDB; EMD-2613; -.
DR   EMDB; EMD-2614; -.
DR   EMDB; EMD-2615; -.
DR   EMDB; EMD-2616; -.
DR   EMDB; EMD-2617; -.
DR   EMDB; EMD-2618; -.
DR   EMDB; EMD-2619; -.
DR   EMDB; EMD-4118; -.
DR   SMR; Q04IN8; -.
DR   PaxDb; 373153-SPD_1726; -.
DR   KEGG; spd:SPD_1726; -.
DR   eggNOG; ENOG502Z7ST; Bacteria.
DR   HOGENOM; CLU_026912_1_0_9; -.
DR   BioCyc; SPNE373153:G1G6V-1864-MONOMER; -.
DR   EvolutionaryTrace; Q04IN8; -.
DR   PHI-base; PHI:6282; -.
DR   PHI-base; PHI:7994; -.
DR   PHI-base; PHI:9909; -.
DR   Proteomes; UP000001452; Chromosome.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015485; F:cholesterol binding; IEA:InterPro.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   GO; GO:0031640; P:killing of cells of another organism; IEA:UniProtKB-KW.
DR   FunFam; 2.60.40.1430:FF:000001; Thiol-activated cytolysin; 1.
DR   Gene3D; 3.30.1040.20; -; 1.
DR   Gene3D; 3.40.30.40; Perfringolysin; 1.
DR   Gene3D; 2.60.40.1430; Perfringolysin, domain 4; 1.
DR   Gene3D; 3.90.840.10; Thiol-activated cytolysin superfamily/Thiol-activated cytolysin, alpha-beta domain; 1.
DR   InterPro; IPR035390; Thiol_cytolys_C.
DR   InterPro; IPR038700; Thiol_cytolys_C_sf.
DR   InterPro; IPR001869; Thiol_cytolysin.
DR   InterPro; IPR036363; Thiol_cytolysin_ab_sf.
DR   InterPro; IPR036359; Thiol_cytolysin_sf.
DR   Pfam; PF17440; Thiol_cytolys_C; 1.
DR   Pfam; PF01289; Thiol_cytolysin; 1.
DR   PRINTS; PR01400; TACYTOLYSIN.
DR   SUPFAM; SSF56978; Perfringolysin; 1.
DR   PROSITE; PS00481; THIOL_CYTOLYSINS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytolysis; Direct protein sequencing; Hemolysis;
KW   Host cell membrane; Host membrane; Lipid-binding; Membrane;
KW   Reference proteome; Secreted; Toxin; Transmembrane;
KW   Transmembrane beta strand; Virulence.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:3552992"
FT   CHAIN           2..471
FT                   /note="Pneumolysin"
FT                   /id="PRO_0000279546"
FT   TRANSMEM        158..171
FT                   /note="Beta stranded"
FT                   /evidence="ECO:0000269|PubMed:28323617,
FT                   ECO:0007744|PDB:5LY6"
FT   TRANSMEM        178..187
FT                   /note="Beta stranded"
FT                   /evidence="ECO:0000269|PubMed:28323617,
FT                   ECO:0007744|PDB:5LY6"
FT   TRANSMEM        256..265
FT                   /note="Beta stranded"
FT                   /evidence="ECO:0000269|PubMed:28323617,
FT                   ECO:0007744|PDB:5LY6"
FT   TRANSMEM        273..285
FT                   /note="Beta stranded"
FT                   /evidence="ECO:0000269|PubMed:28323617,
FT                   ECO:0007744|PDB:5LY6"
FT   MOTIF           427..437
FT                   /note="Conserved undecapeptide"
FT                   /evidence="ECO:0000305"
FT   MOTIF           459..460
FT                   /note="Cholesterol binding"
FT                   /evidence="ECO:0000269|PubMed:20145114"
FT   MUTAGEN         18
FT                   /note="K->A: Loss of hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26403197"
FT   MUTAGEN         63
FT                   /note="T->A: 15% hemolytic activity, forms incomplete rings
FT                   on liposomes."
FT                   /evidence="ECO:0000269|PubMed:27796097"
FT   MUTAGEN         66..68
FT                   /note="NDS->WDW: Loss of hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26403197"
FT   MUTAGEN         66
FT                   /note="N->W: 50% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26403197"
FT   MUTAGEN         68
FT                   /note="S->W: Wild-type hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26403197"
FT   MUTAGEN         85
FT                   /note="N->A: 44% hemolytic activity, forms incomplete rings
FT                   on liposomes."
FT                   /evidence="ECO:0000269|PubMed:27796097"
FT   MUTAGEN         88
FT                   /note="T->E: 4% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26333773"
FT   MUTAGEN         102
FT                   /note="D->A: 1% hemolytic activity, forms linear oligomers
FT                   on liposomes rather than pores."
FT                   /evidence="ECO:0000269|PubMed:27796097"
FT   MUTAGEN         146..147
FT                   /note="Missing: Loss of hemolytic activity, does not bind
FT                   membrane, does not form pores."
FT                   /evidence="ECO:0000269|PubMed:28323617"
FT   MUTAGEN         147
FT                   /note="R->E: 2% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26333773"
FT   MUTAGEN         152
FT                   /note="K->D: 12% hemolytic activity; when associated with
FT                   K-260."
FT                   /evidence="ECO:0000269|PubMed:27796097"
FT   MUTAGEN         168
FT                   /note="D->A: 20% hemolytic activity, inhibits membrane
FT                   insertion, forms prepores on liposomes which detach easily
FT                   and rarely convert to pores."
FT                   /evidence="ECO:0000269|PubMed:28323617"
FT   MUTAGEN         191
FT                   /note="Q->E: 42% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:27796097"
FT   MUTAGEN         205
FT                   /note="D->A: 17% hemolytic activity, forms linear oligomers
FT                   on liposomes rather than pores."
FT                   /evidence="ECO:0000269|PubMed:27796097"
FT   MUTAGEN         205
FT                   /note="D->R: Loss of hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26333773"
FT   MUTAGEN         208
FT                   /note="K->A: 4% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26403197"
FT   MUTAGEN         226
FT                   /note="R->A: 6% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26333773"
FT   MUTAGEN         260
FT                   /note="E->K: 22% hemolytic activity. 12% hemolytic
FT                   activity; when associated with D-152."
FT                   /evidence="ECO:0000269|PubMed:27796097"
FT   MUTAGEN         264
FT                   /note="E->D: 76% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:27796097"
FT   MUTAGEN         304
FT                   /note="T->R: 320-fold decrease in hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26333773"
FT   MUTAGEN         339
FT                   /note="N->R: Loss of hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26333773"
FT   MUTAGEN         405
FT                   /note="T->L: 15% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:27796097"
FT   MUTAGEN         428
FT                   /note="C->A: Wild-type hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:9445384"
FT   MUTAGEN         428
FT                   /note="C->G: 3% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:9445384"
FT   MUTAGEN         428
FT                   /note="C->S: 25% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:9445384"
FT   MUTAGEN         433
FT                   /note="W->F: 1% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:9445384"
FT   MUTAGEN         434..437
FT                   /note="EWWR->AWWA: 5% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:26333773"
FT   MUTAGEN         434
FT                   /note="E->D: 50% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:9445384"
FT   MUTAGEN         434
FT                   /note="E->Q: 20% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:9445384"
FT   MUTAGEN         435
FT                   /note="W->F: 20% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:9445384"
FT   MUTAGEN         436
FT                   /note="W->F: 50% hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:9445384"
FT   MUTAGEN         459..460
FT                   /note="TL->GG: Loss of hemolytic activity, loss of host
FT                   membrane binding, loss of cholesterol binding."
FT                   /evidence="ECO:0000269|PubMed:20145114"
FT   HELIX           2..12
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   TURN            17..21
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          22..24
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          33..39
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          42..61
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          75..79
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           80..83
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          97..101
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           108..111
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          112..117
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           120..137
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   TURN            138..141
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          147..154
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           158..165
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           170..176
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           180..184
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          189..203
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   TURN            210..213
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           222..226
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          229..232
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          234..252
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           259..267
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           277..283
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          285..292
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          301..305
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           307..309
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   HELIX           310..315
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          322..324
FT                   /evidence="ECO:0007829|PDB:4ZGH"
FT   STRAND          327..339
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          344..359
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          361..367
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          369..371
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          373..384
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          390..396
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   TURN            398..401
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          406..414
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          418..431
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          434..444
FT                   /evidence="ECO:0007829|PDB:5CR6"
FT   STRAND          449..469
FT                   /evidence="ECO:0007829|PDB:5CR6"
SQ   SEQUENCE   471 AA;  52899 MW;  966AF46FE2EA5792 CRC64;
     MANKAVNDFI LAMNYDKKKL LTHQGESIEN RFIKEGNQLP DEFVVIERKK RSLSTNTSDI
     SVTATNDSRL YPGALLVVDE TLLENNPTLL AVDRAPMTYS IDLPGLASSD SFLQVEDPSN
     SSVRGAVNDL LAKWHQDYGQ VNNVPARMQY EKITAHSMEQ LKVKFGSDFE KTGNSLDIDF
     NSVHSGEKQI QIVNFKQIYY TVSVDAVKNP GDVFQDTVTV EDLKQRGISA ERPLVYISSV
     AYGRQVYLKL ETTSKSDEVE AAFEALIKGV KVAPQTEWKQ ILDNTEVKAV ILGGDPSSGA
     RVVTGKVDMV EDLIQEGSRF TADHPGLPIS YTTSFLRDNV VATFQNSTDY VETKVTAYRN
     GDLLLDHSGA YVAQYYITWD ELSYDHQGKE VLTPKAWDRN GQDLTAHFTT SIPLKGNVRN
     LSVKIRECTG LAWEWWRTVY EKTDLPLVRK RTISIWGTTL YPQVEDKVEN D
//
